Donepezil

Generic Name
Donepezil
Brand Names
Adlarity, Aricept, Namzaric
Drug Type
Small Molecule
Chemical Formula
C24H29NO3
CAS Number
120014-06-4
Unique Ingredient Identifier
8SSC91326P
Background

In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...

Indication

Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...

Associated Conditions
Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
Associated Therapies
-
Clinical Trials
Related News

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

First Posted Date
2005-09-15
Last Posted Date
2013-02-06
Lead Sponsor
University of Pittsburgh
Target Recruit Count
220
Registration Number
NCT00177671
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Alzheimer's Disease Long-term Follow-up Study (ALF Study)

Phase 4
Completed
Conditions
Alzheimer's Disease
First Posted Date
2005-09-14
Last Posted Date
2021-12-30
Lead Sponsor
Eisai Korea Inc.
Target Recruit Count
114
Registration Number
NCT00165724
Locations
🇰🇷

Yeungnam University Hospital, Daegu, Korea, Republic of

🇰🇷

Changwon Fatima Hospital, Changwon, Korea, Republic of

🇰🇷

Bobath Memorial Hospital, Bundang, Korea, Republic of

and more 4 locations

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Phase 3
Completed
Conditions
Dementia With Parkinson's Disease
First Posted Date
2005-09-14
Last Posted Date
2013-05-10
Lead Sponsor
Eisai Limited
Registration Number
NCT00165815
Locations
🇮🇪

Belfast City Hospital, Belfast, Ireland

🇮🇪

Unit 20 Black Poo Technology Centerl, Blackpool, Ireland

🇩🇪

Parkinson Klinik Wolfach, Wolfach, Germany

and more 1 locations

Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients

Phase 4
Terminated
Conditions
Alzheimer's Disease
Interventions
Drug: DONEPEZIL HYDROCHLORIDE
First Posted Date
2005-09-14
Last Posted Date
2013-11-20
Lead Sponsor
Eisai Korea Inc.
Target Recruit Count
40
Registration Number
NCT00165750
Locations
🇰🇷

Cheonnam University Hospital, Gwangju, Korea, Republic of

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

Phase 3
Completed
Conditions
Dementia, Vascular
First Posted Date
2005-09-14
Last Posted Date
2011-04-01
Lead Sponsor
Eisai Inc.
Target Recruit Count
974
Registration Number
NCT00165737
Locations
🇺🇸

Neurological Associate of Albany PC, Albany, New York, United States

🇺🇸

St. Francis Medical Center, Peoria, Illinois, United States

🇺🇸

University of Texas Mental Sciences Institute, Houston, Texas, United States

and more 2 locations

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Phase 2
Completed
Conditions
Alzheimer Disease
First Posted Date
2005-09-14
Last Posted Date
2010-01-29
Lead Sponsor
Eisai Limited
Registration Number
NCT00165659

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

Phase 2
Completed
Conditions
Alzheimer Disease
Interventions
Drug: lecozotan SR
Drug: Donepezil
First Posted Date
2005-09-08
Last Posted Date
2022-05-06
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
229
Registration Number
NCT00151398

CALM-AD

Phase 4
Conditions
Alzheimer's Disease
First Posted Date
2005-09-02
Last Posted Date
2005-12-14
Lead Sponsor
Institute of Psychiatry, London
Target Recruit Count
190
Registration Number
NCT00142324
Locations
🇬🇧

Queen Elizabeth Psychiatric Hospital, Birmingham, United Kingdom

🇬🇧

Department of Psychiatry for the Elderly, Leicester General Hospital, Leicester, United Kingdom

🇬🇧

Institute for Ageing and Health, Newcastle General Hospital, Newcastle, Newcastle upon Tyne, United Kingdom

and more 5 locations

Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy

First Posted Date
2005-08-31
Last Posted Date
2007-09-14
Lead Sponsor
Groupe Hospitalier Pitie-Salpetriere
Target Recruit Count
16
Registration Number
NCT00139373
Locations
🇫🇷

Centre d'Investigation Clinique-HÔPITAL PITIÉ-SALPETRIERE, Paris, France

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Phase 2
Completed
Conditions
Cognitive Impairment
First Posted Date
2005-02-18
Last Posted Date
2015-11-03
Lead Sponsor
Eisai Limited
Target Recruit Count
165
Registration Number
NCT00103948
Locations
🇺🇸

New York University School of Medicine, New York, New York, United States

🇺🇸

Jose Biller, M.D., Maywood, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy